BRISBANE, Australia, October 31, 2019-- Australian immunology company Kira Biotech today announced it has secured Series A funding of A$20 million to develop therapeutics targeting difficult-to-treat immune system disorders. The funds will help advance Kira Biotech’s lead candidate KB312 through phase 1 human studies. The Series A funding was led by OneVentures, IP Group and the Advance Queensland Business Development Fund. Kira Biotech’s research program focuses on immune tolerance and targets cells and pathways that are key activators of the immune response in patients with autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus and type 1 diabetes.